Cytovac – The Key to Immunotherapy
- Cytovac is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a primary focus towards orphan diseases. The company is a pioneer in the rapidly developing field of personalized cell-based therapies for solid tumors, and is using the proprietary ALECSAT platform to generate best-in-class therapeutics to treat cancers with a high unmet medical need.
- Cytovac has a phase Ib investigator initiated exploratory trial ongoing in Triple Negative Breast Cancer (TNBC).
- Cytovac have completed four phase I trials in glioblastoma multiforme, pancreatic cancer and prostate cancer.
- The completed phase I trial in the aggressive brain cancer, glioblastoma multiforme, showed indications of prolonged survival. Glioblastoma has an average median survival of 15 months with today’s treatment.
- The complete phase II data set in Glioblastoma (progression free survival as primary endpoint) will be published during 2021.
- Other early phase I or II trials are being planned as stand alone or in partnership with other companies.
- Cytovac has established an approved GMP manufacturing facility and research department which also support scientific development for other partners.
- Cytovac has filed a patent for treating elder and severely ill COVID-19 patients with its ALECSAT platform technology.
- The management team and board have extensive experience from development and commercialization of biotech products.
